How to go Paperless in an FDA-Regulated Environment using Electronic Workflow Signature Approvals and Electronic Records
|Date||:||23rd July 2019|
|Time||:||10:00 AM PST | 01:00 PM EST|
This course is intended to provide specific guidelines for coaching attendees in the concepts of 21 CFR Part 11, namely the FDA requirements for using electronic records and electronic signatures (ER/ES), and the best practices for implementing these technologies in a regulated environment. The use of electronic records and signatures enables a company to conduct business in a paperless environment. However, this is only if the company adheres to the specific requirements put forth by the FDA in their guidance for ER/ES. The paperless environment means that all signatures will be obtained through a software-enabled workflow system that routes the key documents to specifically approved signers.
The workflow typically includes tracking of the status of the document, indicating where it is in the approval process. It also allows for signers to reject a document and request that either it be withdrawn altogether or modified in some manner. The key to successful compliance of a paperless workflow and approval environment is set up the right security and access rights, and authenticating signatures effectively.
Why Should You Attend:
The attendees will learn how to develop a standard approach to establishing and maintaining the use of ER/ES to handle records and approvals in an FDA regulated environment. There are specific best practices that should be considered before choosing to implement these capabilities and operate in a “paperless” environment, and these will be discussed. We will discuss the pros and cons of using ER/ES, and talk about the ramifications of choosing to do so. The attendee will be prepared to make a determination about applying ER/ES capabilities in their workplace and will be able to implement the best practices for maintaining ER/ES in a compliant manner.
We will touch on those areas that are critical to meeting the requirements set forth in FDA’s 21 CFR Part 11, including security and newer technologies that are emerging for capturing, analyzing, storing and reporting information for decision-making purposes.
It’s important to look at what are some of the threats and challenges of using ER/ES, and what methods you can use to mitigate these. Similarly, it is important to identify opportunities that might help companies decrease the cost of compliance and improve operational efficiencies and effectiveness through the use of ER/ES.
Areas Covered in the Session:
- FDA’s 21 CFR Part 11 guidance for electronic records and signatures
- Pros and cons of implementing ER/ES capability
- Cost-benefit analysis of implementing ER/ES capability
- Risks associated with ER/ES implementation and potential mitigation
- Organizational change management required to successfully implement and using ER/ES capability
- Key roles and responsibilities required in the process of implementing, using and supporting systems with ER/ES capability
- Integration of ER/ES capability in existing applications
- Documenting ER/ES rationalization
- Preparing for an FDA audit that will include scrutiny of applications with ER/ES capability
- Examples of companies that have implemented ER/ES capability and discuss the rationale behind it, cost-benefit analysis conducted, risk assessment conducted and some of the outcomes, both successful and unsuccessful Compliance and Audit Managers
Who will Benefit:
- Information Technology Analysts
- Information Technology Developers and Testers
- QC/QA Managers and Analysts
- Clinical Data Managers and Scientists
- Analytical Chemists
- Laboratory Managers
- Automation Analysts
- Computer System Validation Specialists
- GMP Training Specialists
- Business Stakeholders/Subject Matter Experts
- Business System/Application Testers
- Any consultants working in the tobacco or life science industries who are involved in computer system implementation, validation and compliance.
Carolyn Troiano has more than 35 years of experience in the tobacco, pharmaceutical, medical device, and other FDA-regulated industries. She has worked directly, or on a consulting basis, for many of the larger pharmaceutical and tobacco companies in the US and Europe, developing and executing compliance strategies and programs.